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being associated with a rise in the average of laboratory tests and more hospitaliza-
tions. Direct cost for patients ranged from 6,066.8€ (> 500 cells/mL) to 7,654.3€ (< 200 
cells/mL). ConClusions: The total direct cost of HIV-infection seems to increase 
with advanced disease. Considering the reduction of available resources, especially 
in a country such as Greece, where austerity measures take place, effective disease 
management represents a major challenge, and the improvement of health services 
provided to HIV patients is more than compelling.
PIN44
BurdeN of dIsease Caused By INflueNza IN GermaNy - a retrosPeCtIve 
ClaIms dataBase aNalysIs
Haas J.S.1, Wutzler P.2, Braun S.1
1HERESCON GmbH, Hannover, Germany, 2Jena University Hospital, Friedrich-Schiller University, 
Jena, Germany
objeCtives: Seasonal influenza occurs in annual epidemics usually peaking dur-
ing winter. The seasonal influenza virus can cause mild to severe illness and poses 
a burden for patients of all age groups. The objective of this study is to assess the 
disease burden and vaccination-rates based on claims data in different age groups 
for the influenza season 2012/2013 in Germany. Methods: We conducted a ret-
rospective claims data analysis using the Health Risk Institute research database, 
containing anonymized data of 3,953,260 individuals (appr. 4.9% of the German 
population). The study period comprised 1 October 2012 to 30 June 2013, patients 
were identified based on the ICD-10-GM codes for influenza. Vaccine-rates were cal-
culated by identifying documented vaccinations. The disease burden was assessed 
based on occurring secondary diseases and health services utilization in the inpa-
tient and outpatient sector. The relative frequency of the most common concomi-
tant diseases (otitis media, pneumonia) was evaluated and compared to individuals 
not infected with influenza. Results were compared and validated against existing 
evidence. Results: We observed 65,826 patients with a documented influenza dur-
ing the influenza season 2012/2013. The occurrence of otitis media and pneumonia 
was higher in all age groups compared to the non-influenza-infected population and 
especially high in children. A total of 848 influenza-related hospitalizations were 
identified with a mean duration of 6 days, amounting to € 4,945,686 and 8,532 days 
of inpatient care. Overall, 65% of these hospitalizations were caused by influenza 
(principal diagnosis), and even over 80% for patients aged 2-17 years. Moreover, total 
outpatient costs amounted to € 14,947,976. Finally, vaccination-rates were below 4% 
for children and 37% for patients aged > 60. ConClusions: Seasonal influenza 
can cause severe outcomes leading to hospitalizations and excess costs. Especially 
influenza-infected children are affected by concomitant diseases resulting in a 
higher disease burden. Furthermore, documented vaccination-rates are quite low.
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objeCtives: The hepatitis C virus (HCV) induces several pathological conditions 
worldwide with a substantial medical and economic burden. The objective of this 
study is to estimate the average annual cost incurred by the National Health Service 
(NHS) as well as society due to HCV in Italy. Methods: A probabilistic incidence-
based cost of illness model was developed to estimate an aggregate measure of the 
economic burden associated with HCV-related diseases either in terms of direct or 
indirect costs (impact of absenteeism computed according to the human capital 
method). A systematic literature review was carried out to reveal both epidemiologi-
cal and economic data. Furthermore, a one-way probabilistic sensitivity analysis 
with 5,000 Monte Carlo simulations was performed, in order to test the robustness 
of results and define the proper 95%CI. Results: Overall, the total economic burden 
associated with HCV-related diseases was estimated in € 1,05 (95%CI: € 0,61-€ 1,61) 
billion. A percentage equal to 61,4% were associated with indirect costs (95% CI: 
€ 0,37-€ 0,99 billion) and 38,6% with direct costs (95% CI: € 0,23-€ 0,63 billion). For 
chronic hepatitis C, cirrhosis, hepatocellular carcinoma (HCC), liver transplantation 
and death from causes related to HCV was estimated an average annual economic 
burden amounting to € 0,26 (95%CI: € 0,14-€ 0,41), € 0,55 (95%CI: € 0,30-€ 0,87), € 
0,051 (95%CI: € 0,0001-€ 0,25) € 0,05 (95%CI: € 0,03-€ 0,08) and € 0,15 (95%CI: € 0,06-€ 
0,27) billion, respectively. ConClusions: Italy is one of the European countries 
with the highest number of people with chronic HCV infection, the leading cause 
of cirrhosis, HCC and liver-related death. HCV-related diseases causes a significant 
cost for Italian NHS, especially for each case of liver transplantation. These highly 
debilitating and life-threatening complications generate a rather large amount of 
indirect costs for the Italian society as well.
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objeCtives: During the influenza epidemic period (2009-2010) 17 % of Ukrainian 
population were sick. The aim was to assess the dynamics of incidence rates. We 
analyzed the costs of treating influenza and acute respiratory infections (ARI) in the 
four stages of medical care: 1 - primary care (PCP), 2-out-patient, 3-hospital, 4-inten-
sive care unit during the period 2009-2010 (pandemic) vs 2010-2011. Methods: We 
used the statistic data of the MoH of Ukraine, the incidence of influenza and ARI, and 
method “cost of illness” per 1 patient. Results: In 2009-2010 influenza rate and ARI 
was 472,6 per 100000 population. The vaccination coverage was 239,104 people, that 
representing 0.518% of the total population. In 2010-2011 the ifluenza rate and ARI was 
420.9 per 100000, respectively. The vaccination coverage was 602911 persons during 
2010-2011 years, that’s 1,312% of the total population. We obtained the following costs 
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objeCtives: Examine the economic burden and health care utilizations of the 
chronic hepatitis C (CHC) in the U. S. veteran population. Methods: A retrospective 
database analysis was performed using the U. S. Veterans Health Administration 
Medical SAS datasets (01OCT2007-30SEP2012). Patients diagnosed with CHC 
(International Classification of Disease 9thRevision Clinical Modification [ICD-9-CM] 
codes 070.44, 070.54, 070.70, 070.71) were identified, and the first diagnosis date 
served as the index date. A comparator group was created by identifying patients 
without a CHC diagnosis but of the same age, region, gender and index year, and 
matched according to baseline Charlson Comorbidity Index scores. The index date 
for the comparator group was randomly chosen to reduce selection bias. A 1-year 
continuous enrollment period pre- and post-index date was required for both 
groups. One-to-one propensity score matching (PSM) was used to compare health 
care costs and utilizations during the follow-up period between the cohorts, adjust-
ing for baseline demographic and clinical characteristics. Results: Eligible patients 
(N= 87,837) were identified for the CHC and comparison cohorts. After applying 
1:1 PSM, a total of 69,809 patients were matched from each group and baseline 
characteristics were well-balanced. CHC patients were more likely to be hospital-
ized (33.47% vs. 2.42%, p< 0.0001) and had more emergency room (ER) (28.55% vs. 
6.68%, p< 0.0001), physician office (98.65% vs. 53.56%, p< 0.0001), outpatient (98.81% 
vs. 54.46%, p< 0.0001) and pharmacy visits (88.73% vs. 57.18%, p< 0.0001), resulting 
in higher health care costs for inpatient ($11,303 vs. $691, p< 0.0001), ER ($345 vs. 
$60, p< 0.0001), outpatient ($5,540 vs. $1,382, p< 0.0001), physician office ($4,956 
vs. $1,230, p< 0.0001), pharmacy ($947 vs. $433, p< 0.0001) and total costs ($17,789 vs. 
$2,506, p< 0.0001) for CHC patients, relative to comparison patients. ConClusions: 
U.S. veterans diagnosed with CHC were more likely to have higher health care 
resource utilization and were associated with a higher economic burden compared 
to matched controls.
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objeCtives: To accurately estimate hospitalization costs of Community-Acquired 
Pneumonia (CAP) in elderly in the Netherlands. Methods: This observational 
study was part of the CAPiTA-trial [1] and was conducted in 54 hospitals in the 
Netherlands between October 2008 and August 2013. CAPiTA participants with a sus-
picion of CAP were included. CAP was diagnosed on clinical and radiographic criteria 
according to the CAPiTA protocol. A re-admission within 30 days was considered as 
one episode. Data on health care use were collected prospectively using clinical files. 
Hospitalization costs were stratified by age-group (65-74, 75-84 and ≥ 85) and risk cat-
egories based on comorbidities (high (i.e. immunocompromised patients), medium 
(i.e. presence of other chronic conditions) and low). Costs are presented for the year 
2012. Results: 3,141 suspected CAP episodes were included. 1,835 confirmed CAP 
episodes (58.4%) were reported of which 124 cases were readmissions (6.8%). The 
first admission resulted in an overall mean length of hospital stay of 10.94 (SD ±9) 
days, in-hospital mortality rate of 10.7%, and average costs of € 7,219 (95% CI [€ 6,653, 
€ 7,833]). General ward nursing cost accounted for 67.4% of all costs and ICU nursing 
for 27.8%. For the age-categories 65-74, 75-84 and ≥ 85 mean length of hospital stay 
was respectively 11.23,10.86 and 10.56 days (p= 0.534), fatality rate was 7,8%, 10,6%, 
and 15,5% (p= 0,001) and mean hospitalization costs were € 7,985, € 7,240, € 5,774 
(p= 0.041). When stratified by risk, the highest risk group showed the lowest mean 
costs (€ 6,551, p= 0.019) and the highest mortality (21%). ConClusions: Health care 
costs decline with age and risk severity. The eldest age group experienced shorter 
ICU admissions and high mortality. Patients with medium and high risk for devel-
oping CAP showed a higher mortality rate and lower costs. 1. Hak, E., et al., Neth J 
Med, 2008.66 (9): p. 378-83.
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objeCtives: HIV-infection nowadays represents a chronic disease of high com-
plexity affecting populations worldwide. Highly active antiretroviral therapy, where 
available, has resulted in prolonged life expectancy and increased quality of life, 
through an ever-increasing cost of HIV-infection. The present study aimed at esti-
mating the health resources consumed by HIV-infected patients and their respective 
direct costs, on an annual basis, in Greece. Methods: A retrospective study was 
performed in order to collect data from the medical records of 447 HIV-infected 
patients, followed in an Infectious Diseases Unit in Athens. The survey included all 
services and antiretroviral treatment that patients received in one year as well as 
their demographic data. The subjects of the study were stratified in three health 
states according to the CD4+ counts, as defined by the CDC classification system 
for HIV infection. The cost analysis evaluating the direct cost of HIV-infection was 
undertaken from a third-party payer perspective. Results: The annual direct cost 
was calculated at 6,860.3€ /patient, the largest part being attributed to antiretroviral 
therapy (5,741.8€ , p= NS). The respective cost for providing health care services was 
estimated at 1,118.5€ , with laboratory tests representing 13.5% of total cost (P< 0.05), 
while hospitalization and outpatient visits accounted for 2.3% (p< 0.05) and 0.5% 
(p= NS) respectively. Overall, direct cost/patient increased for lower CD4+ counts, 
